GB2054371A - Long-acting parenteral compositions of haloperidol and bromperidol derivatives - Google Patents
Long-acting parenteral compositions of haloperidol and bromperidol derivatives Download PDFInfo
- Publication number
- GB2054371A GB2054371A GB8018117A GB8018117A GB2054371A GB 2054371 A GB2054371 A GB 2054371A GB 8018117 A GB8018117 A GB 8018117A GB 8018117 A GB8018117 A GB 8018117A GB 2054371 A GB2054371 A GB 2054371A
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- haloperidol
- bromperidol
- long
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Abstract
Long-acting neuraleptic compositions for parenteral, in particular intramuscular or subcutaneous, administration, comprise a decanoate ester of haloperidol or bromperidol in sesame oil as a solvent. The esters may be prepared by known methods.
Description
SPECIFICATION
Long-acting parenteral compositions of haloperidol and bromperidol derivatives
Haloperidol, being chemically designated as 4 -L4 (4 - chlorophenyl) -4 - hydroxy - 1 - piperidinylj - 1 - (4 -fluorophenyl) - 1 - butanone, and bromperidol, being chemically designated as 4 -[4 - (4 bromophenyl) -4 - hydroxy - 1 - piperidinylj - 1 - (4 - fluorophenyl) - 1 - butanone, are both well-known psychotropic agents belonging to the class of4 piperidinols which are described in Japanese Pat.
No.300,049.
Structurally, haloperidol and bromperidol are represented by the formula
wherein X is respectively chloro (haloperidol) or bromo (bromperidol).
The compounds are powerful psychotropic drugs which can be used in psychotropic therapy permitting the return to normal pursuits of patients who otherwise might require prolonged or repeated hospitalization.
After initial recovery or discharge of the patients it is advisable and mostly indispensable to continue the therapy with a maintenance dose to prevent the frequent relapses which are recorded at varying lengths of time after the suspension of treatment.
Although parenteral administration is replaced by oral administration, as soon as possible, many times it is not practicable and then the frequency of injection gets burdensome. This frequency of injection, which is oftentimes accompanied by tissue irritation, makes it desirable to find a composition for intramuscular administration which preserves the psychotropic properties of haloperidol or bromperidol while the frequency of administration can be reduced.
In U.S. Pat. No. 3,408,356 there are described a series of longchain esters of piperidinols and in particular, long-chain esters of 1 - (4 - fluorophenyl) - 4 {4 -[ - 3 - (trifluoromiethyl) phenyl )J -4 - hydroxy - 1 - piperidinyl} - 1 - butanone, which is generally known as trifluperidol ortriperidol. Also disclosed are pharmaceutical compositions comprising said long-chain esters in suitable vehicles. According to
U.S. Pat. No. 3,408,356 the concerned compounds exhibit prolonged tranquilizing activity, particularly in the treatment of mental disorders.
The present invention is specifically concerned with pharmaceutical compositions comprising a decanoic acid ester of haloperidol or bromperidol in sesame oil as a solvent.
The decanoic acid esters, which are used as active ingredients in the compositions according to the present invention, may be represented by the formula
wherein X is chloro or bromo.
The subject compositions of the present invention are highly efficaceous and at the same time remarkably safe and almost completely free of any undesired side-effects. More especially, when administered to warm-blooded animals, the said compositions provoke a long-lasting and nevertheless uniform psychotropic effect, which can be varied in duration to up to several weeks depending upon the concentration and the amount of decanoic acid ester which is present in the composition.
The compositions of the present invention have been found remarkably free of excitatory and extrapyramidal side-effects which are rather frequently encountered during trifluperidol therapy. It is evident that a reduction or even complete absence of such side-effects are a prerequisite to a therapy with long-acting psychotropic agents since such effects, if existing, will continue during a long period of time, even after interruption of the treatment. The reduction of these side-effects or even the complete disappearance thereof renders the compositions of the present invention particularly attractive for longterm parenteral therapy. In this respect the subject compositions show a marked superiority over any long-acting psychotropic compositions presently in use.
It has been found that the intramuscular or subcutaneous administration of piperidinols such as haloperidol and bromperidol is often associated with tissue irritation. Quite unexpectedly, the compositions of the present invention are found to be sub stantial ly free of any tissue irritation.
The compounds of formula (II) may easily be prepared by acylating haloperidol (I-a) or bromperidol (I-b)with decanoyl chloride (III).
(I-a) X = Cl (I-b) X Said acylating reaction is preferably carried out
following art-known acylating procedures, such as
by stirring the reactants together, if desired, in the
presence of a suitable solvent, e.g., N,N -dimethyl- formamide, N,N dimethylacetamide, acetonitrile, 2
- propanone, and the like. Somewhat elevated temp
eratures are appropriate to enhance the rate of the
reaction. Most preferably the reaction is carried out
in the presence of an appropriate base, e.g., sodium carbonate, pyridine and the like, to captivate the hydrochloric acid which is liberated during the course of the reaction.
The preparations of the piperidinols of formula (I) are generally known. They may be prepared following one of the procedures described in the literature, e.g., following one of the procedures described in
Japanese Pat. No. 300,049.
The effectiveness and the extended duration of action ofthe compositions comprising a decanoate ester of haloperidol or bromperidol can be demonstrated by apomorphine emesis studies. Apomorphine hydrochloride is a central emetic which induces vomiting within a few minutes after subcutaneous injection, except when the test-animals are pretreated with effective neuroleptics. The duration of effectiveness may be determined by chronic induction of apomorphine emesis.
Appropriately selected dogs are injected intramuscularly in the biceps femoris with a test dose. Four hours after dosing and 90 minutes following feeding, apomorphine hydrochloride (0.31 mg/kg) is injected subcutaneously. The animals are observed during 30 minutes following the injection.
Thereafter, the apomorphine hydrochloride is administered daily, 90 minutes following feeding, and observations of the response made during 30 minutes. The duration of action is the period between the first absence of emetic response and the first of three consecutive positive emetic responses.
Table I illustratesthe median duration of action, the test being carried out on 5 dogs.
Table I
Compound Dose Median duration of mg/kg action (days) haloperidol 2.5 5 haloperidol decanoate 2.5 21 bromperidol 1.5 4 bromperidol decanoate 1.5 19 The compositions according to the present invention may contain a suitable antimicrobial preservative but other additives normally are not necessary.
An example of such a preservative is benzyl alcohol.
The compositions may be prepared in a conventional manner, e.g., by admixing the ester with the preservative, if present, and then with the sesame oil. The concentration of the decanoic acid ester may be from about 30 to about 150 mg per milliliter.
By the present invention there is also provided a method of effecting psychotropic therapy which comprises administering to a subject needing such therapy, a psychotropically effective amount of a compound of formula (II) in a composition according to the invention. Psychotropic therapy may generally be effected by administering such compositions in an amount sufficient to supplyfrom 0.4 to 20 mg of active ingredient per kg of body weight.
The preferred route of administration is intramuscular although subcutaneous administration may also be employed.
The following examples are intended to illustrate and not to limit the scope of the present invention.
Example I
To a warmed suspension of 37.6 parts of 4 -[4 - (4 chlorophenyl) -4 - hydroxy -1 - piperidinylj - 1 - (4 - fluorophenyl) - 1 - butanone in 320 parts of prop
anone are added successively 15.3 parts of N,N
diethylethanamine and 28.9 parts of decanoyl
chloride. The resulting mixture is heated and refluxed for 18 hours. After cooling the mixture is filtered and the filtrate is evaporated under reduced pressure, yielding a residue which is triturated with 1,1' -oxybisethaneto separate the triethylamine hydrochloride by-product.The filtrate is concentrated and purified by column-chromatography using 1,1' - oxybisethane as eluent, yielding 33 parts (66.3%) of 4 - (4 - chlorophenyl ) -1 - L4 - (4 - fluorophenyl) - 4 - oxobutylj - 4- piperidinyl decano- ate, as a viscous oil.
Example II To a stirred and warm (60"C) solution of 10 parts of 4 (4 - (4!- bromophenyl) -4 - hydroxy -1 piperidinylt - t - (4 - fluorophenyl ) - 1 - butanone in 90 parts of N,N - dimethylformamide are added dropwise 5.76 parts decanoyl chloride. Upon completion, stirring at 600C is continued overnight. The reaction mixture is cooled and poured onto water. The mix ture is alkalized with a sodium hydroxide solution 2N. The aqueous phase is decanted and the sticky oil is dissolved in 1,1' - oxybisethane at room tempera- ture whereupon the unreacted starting material is filtered off. The 1,1' oxybisethane -phase is washed twice with water, dried, filtered and evaporated. The oily residue is purified by columnchromatography over silica gel using 1,1' oxybisethane as eluent, yielding 8.4 parts of4 - (4 - bromophenyl) - 1 -[4 - (4 fluorophenyl) - 4 - oxobutylj - 4- piperidinyl decanoate as an oii.
Example III Injectable compositions are prepared by intermixing the components:
composition A:
Haloperidol decanoate 70.5 grams
Benzyl alcohol 12 grams
Sesame oil, q.s. ad 1 liter
composition B:
Haloperidol decanoate 141 grams
Benzyl alcohol 12 grams
Sesame oil, q.s. ad 1 liter
composition C:
Bromoperidol decanoate 34 grams
Benzyl alcohol 12 gram
Sesame oil, q.s. ad 1 liter
composition D:
Bromperidol decanoate 136 grams
Benzyl alcohol 12 grams
Sesame oil, q.s. ad 1 liter.
Claims (8)
1. A psychotropic composition, suitable for parenteral administration, comprising sesame oil as a solvent and as an active ingredient an effective psychotropic amount of a decanoic acid ester having the formula:
wherein X is a chlorine or bromine atom.
2. A composition as claimed in claim 1 comprising from 30 mg to 150 mg of 4 - (4 - chlorophenyl) -1 -[4-(4-fluorophenyl )-4-oxo-butylJ -4
piperidinyl decanoate per ml.
3. A composition as claimed in claim 1 comprising from 30 mg to 150 mg of 4 - (4 - bromophenyl) - 1 -[4-(4-fluorophenyl)-4-oxo-butylj - 4 - piperidinyl decanoate per ml.
4. A composition as claimed in claim 2 which is suitable for intramuscular and subcutaneous administration.
5. A composition as claimed in claim 3 which is suitable for intramuscual and subcutaneous administration.
6. Acomposition as claimed in any one ofthe
preceding claims which contains an antimicrobial preservative.
7. A composition as claimed in claim 6 wherein the preservative in benzyl alcohol.
8. A composition as claimed in claim 1 substantially as hereinbefore described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8082679A JPS568318A (en) | 1979-06-28 | 1979-06-28 | Non oral long acting composition of haloperidol and bromperidol derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2054371A true GB2054371A (en) | 1981-02-18 |
GB2054371B GB2054371B (en) | 1983-08-03 |
Family
ID=13729223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8018117A Expired GB2054371B (en) | 1979-06-28 | 1980-06-03 | Long-acting parenteral compositions of haloperidol and bromperidol derivatives |
Country Status (9)
Country | Link |
---|---|
JP (1) | JPS568318A (en) |
BE (1) | BE883994A (en) |
CY (1) | CY1255A (en) |
DE (1) | DE3024305A1 (en) |
FR (1) | FR2460932A1 (en) |
GB (1) | GB2054371B (en) |
HK (1) | HK83384A (en) |
KE (1) | KE3427A (en) |
NL (1) | NL190775C (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260070A1 (en) * | 1986-09-11 | 1988-03-16 | H. Lundbeck A/S | The acetic acid ester of haloperidol and pharmaceutical compositions thereof |
US5428036A (en) * | 1990-10-03 | 1995-06-27 | H. Lundbeck A/S | Sertindole prodrugs, compositions and use |
US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
US8304447B2 (en) | 2007-05-31 | 2012-11-06 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
US8309593B2 (en) | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
US8389517B2 (en) | 2008-07-28 | 2013-03-05 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
CN103301461A (en) * | 2012-03-08 | 2013-09-18 | 江苏豪森药业股份有限公司 | Long-acting injectable preparation, preparation method and application thereof |
US8716327B2 (en) | 2006-05-09 | 2014-05-06 | Genzyme Corporation | Methods of treating fatty liver disease |
US8912177B2 (en) | 2007-10-05 | 2014-12-16 | Genzyme Corporation | Method of treating polycystic kidney diseases with ceramide derivatives |
US9861699B2 (en) | 2012-09-19 | 2018-01-09 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US9993556B2 (en) | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
US10004807B2 (en) | 2012-03-19 | 2018-06-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
US10085980B2 (en) | 2014-03-20 | 2018-10-02 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
US10226458B2 (en) | 2011-03-18 | 2019-03-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
WO2021143746A1 (en) * | 2020-01-14 | 2021-07-22 | 中国科学院上海药物研究所 | Non-aqueous sustained release drug delivery system |
US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
WO2023281404A1 (en) | 2021-07-07 | 2023-01-12 | Richter Gedeon Nyrt. | Controlled release injectable cariprazine formulation |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE188375T1 (en) * | 1992-11-17 | 2000-01-15 | Yoshitomi Pharmaceutical | A SUSTAINED RELEASE MICROBLADE CONTAINING AN ANTIPSYCHOTIC AND METHOD FOR THE PRODUCTION THEREOF |
EP0937053A1 (en) * | 1996-10-31 | 1999-08-25 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Sustained-release derivatives of hydroxylated analogs of substituted 1- 2 bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use as noncompetitive antagonists of dopamine reuptake |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3408356A (en) * | 1965-08-31 | 1968-10-29 | Squibb & Sons Inc | Long chain esters of 4'-fluoro-4-[4-hydroxy-4-(alpha, alpha, alpha-trifluorotolyl)piperi-dino]butyrophenone and the like |
DE1695194A1 (en) * | 1966-07-11 | 1971-03-18 | Hoffmann La Roche | Process for the preparation of piperidine derivatives |
US3850935A (en) * | 1971-10-16 | 1974-11-26 | Sumitomo Chemical Co | Process for producing piperidine derivatives by degrading quaternary piperidinium salts |
-
1979
- 1979-06-28 JP JP8082679A patent/JPS568318A/en active Pending
-
1980
- 1980-06-03 GB GB8018117A patent/GB2054371B/en not_active Expired
- 1980-06-03 CY CY1255A patent/CY1255A/en unknown
- 1980-06-20 NL NL8003583A patent/NL190775C/en not_active IP Right Cessation
- 1980-06-25 BE BE0/201165A patent/BE883994A/en not_active IP Right Cessation
- 1980-06-27 FR FR8014443A patent/FR2460932A1/en active Granted
- 1980-06-27 DE DE19803024305 patent/DE3024305A1/en active Granted
-
1984
- 1984-07-20 KE KE3427A patent/KE3427A/en unknown
- 1984-11-01 HK HK833/84A patent/HK83384A/en not_active IP Right Cessation
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260070A1 (en) * | 1986-09-11 | 1988-03-16 | H. Lundbeck A/S | The acetic acid ester of haloperidol and pharmaceutical compositions thereof |
US5428036A (en) * | 1990-10-03 | 1995-06-27 | H. Lundbeck A/S | Sertindole prodrugs, compositions and use |
US9532976B2 (en) | 2004-11-10 | 2017-01-03 | Genzyme Corporation | Method of lowering blood glucose |
US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
US8716327B2 (en) | 2006-05-09 | 2014-05-06 | Genzyme Corporation | Methods of treating fatty liver disease |
US9556155B2 (en) | 2006-05-09 | 2017-01-31 | Genzyme Corporation | Methods of treating fatty liver disease |
US8304447B2 (en) | 2007-05-31 | 2012-11-06 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
US9745294B2 (en) | 2007-05-31 | 2017-08-29 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
US8940776B2 (en) | 2007-05-31 | 2015-01-27 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
US10220039B2 (en) | 2007-10-05 | 2019-03-05 | Genzyme Corporation | Method of treating polycystic kidney diseases with ceramide derivatives |
US8912177B2 (en) | 2007-10-05 | 2014-12-16 | Genzyme Corporation | Method of treating polycystic kidney diseases with ceramide derivatives |
US8389517B2 (en) | 2008-07-28 | 2013-03-05 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
US9481671B2 (en) | 2008-07-28 | 2016-11-01 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
US8729075B2 (en) | 2008-07-28 | 2014-05-20 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
US9272996B2 (en) | 2008-10-03 | 2016-03-01 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
US9744153B2 (en) | 2008-10-03 | 2017-08-29 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
US8309593B2 (en) | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
US10226458B2 (en) | 2011-03-18 | 2019-03-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
CN103301461A (en) * | 2012-03-08 | 2013-09-18 | 江苏豪森药业股份有限公司 | Long-acting injectable preparation, preparation method and application thereof |
CN103301461B (en) * | 2012-03-08 | 2018-09-07 | 江苏豪森药业集团有限公司 | A kind of long acting injection and its preparation method and application |
US9993556B2 (en) | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
US10004807B2 (en) | 2012-03-19 | 2018-06-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
US10639376B2 (en) | 2012-09-19 | 2020-05-05 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US9861699B2 (en) | 2012-09-19 | 2018-01-09 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US10342877B2 (en) | 2012-09-19 | 2019-07-09 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US11097006B2 (en) | 2012-09-19 | 2021-08-24 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US11969469B2 (en) | 2012-09-19 | 2024-04-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US10238651B2 (en) | 2014-03-20 | 2019-03-26 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
US10085980B2 (en) | 2014-03-20 | 2018-10-02 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
US10813928B2 (en) | 2014-03-20 | 2020-10-27 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
US11406632B2 (en) | 2014-03-20 | 2022-08-09 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
US11931355B2 (en) | 2014-03-20 | 2024-03-19 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
WO2021143746A1 (en) * | 2020-01-14 | 2021-07-22 | 中国科学院上海药物研究所 | Non-aqueous sustained release drug delivery system |
WO2023281404A1 (en) | 2021-07-07 | 2023-01-12 | Richter Gedeon Nyrt. | Controlled release injectable cariprazine formulation |
Also Published As
Publication number | Publication date |
---|---|
NL190775C (en) | 1994-08-16 |
KE3427A (en) | 1984-08-10 |
GB2054371B (en) | 1983-08-03 |
CY1255A (en) | 1984-08-31 |
FR2460932A1 (en) | 1981-01-30 |
FR2460932B1 (en) | 1984-11-16 |
NL8003583A (en) | 1980-12-30 |
BE883994A (en) | 1980-12-29 |
DE3024305C2 (en) | 1989-12-07 |
HK83384A (en) | 1984-11-09 |
DE3024305A1 (en) | 1981-01-22 |
JPS568318A (en) | 1981-01-28 |
NL190775B (en) | 1994-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2054371A (en) | Long-acting parenteral compositions of haloperidol and bromperidol derivatives | |
JPS61152662A (en) | Novel bicyclic heteroarylpiperazine compound, medicine and manufacture | |
DE2706977A1 (en) | BENZOESAEURS AND THEIR DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF | |
DE3200304A1 (en) | 3-AMINOPROPOXYARYL DERIVATIVES, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM | |
EP0102194B1 (en) | 3-phenoxy-1-azetidinecarboxamides and their use and preparation | |
DE3686245T2 (en) | AMID DERIVATIVES AND ANTI-ALLERGIC AGENTS THAT INCLUDE. | |
DE2204574A1 (en) | PROCESS FOR THE PRODUCTION OF 3-AMINOBENZO-1,2,4-TRIAZINE-DI-N-OXIDES (1,4) | |
FR2471381A1 (en) | ERGOLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR USE AS MEDICAMENTS | |
DE3216843C2 (en) | 3-Thiomethyl-pyridine derivatives, processes for their preparation and pharmaceuticals containing these compounds | |
DE2407715A1 (en) | CEPHALOSPORINE, THE METHOD FOR MANUFACTURING IT AND ITS USE AS A MEDICINAL PRODUCT | |
DE2538424A1 (en) | NEW OXAZOLIDINONE, METHOD OF PREPARATION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
CH615914A5 (en) | ||
DE2944037A1 (en) | ANTI-HYPERTENSIVE SULFURING COMPOUNDS | |
DE1134079B (en) | Process for the preparation of N-fluoroacetyl and N-chloroacetylpiperazines | |
DE3785076T2 (en) | PYRIDO (4,3-D) PYRIMIDINE DERIVATIVES. | |
DE69909592T4 (en) | USE OF THIADIAZOLO [4,3-A] PYRIDINE DERIVATIVES | |
DE2257639A1 (en) | NEW ESTERS AND ETHERS OF KETOXIMES, PROCESS FOR THEIR PRODUCTION AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS | |
DE2131330A1 (en) | Imidazo [1,2-a] benzimidazole derivatives and processes for making the same | |
DE3120543A1 (en) | 2- (ALK-1'-EN-1'-YL) -CHINOXALIN-1,4-DIOXYD DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THESE COMPOUNDS AND / OR A KNOWN 2- (ALK-1'-EN-1'-YL ) -CHINOXALIN-1,4-DIOXYD DERIVATIVE-CONTAINING MEDICINAL PRODUCTS, ASPENDANT PRODUCTS, FEED PRODUCT CONCENTRATES AND FEED PRODUCTS | |
DE1226105B (en) | Process for the preparation of new 3,4-dihydroquinazolone (4) derivatives | |
DE1695790C3 (en) | S-phenoxythionocarbonyl derivatives of vitamin B deep 1 | |
US4920126A (en) | Barbituric acid derivative and treatment of leukemia and tumors therewith | |
DE2801980A1 (en) | 4-HYDROXY-2-BENZIMIDAZOLINE-THIONE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
EP0254852B1 (en) | Hydroxamic acid derivatives and pharmaceutical compositions comprising them | |
AT375346B (en) | METHOD FOR PRODUCING NEW SUBSTITUTED 1-BENZOYL-2-PHENYLIMINO IMIDAZOLIDINES AND THEIR SALTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE20 | Patent expired after termination of 20 years |
Effective date: 20000602 |